Cargando…
Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization
Immunization is key to preventing infectious diseases, a leading cause of death early in life. However, due to age-specific immunity, vaccines often demonstrate reduced efficacy in newborns and young infants as compared to adults. Here, we combined in vitro and in vivo approaches to identify adjuvan...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732947/ https://www.ncbi.nlm.nih.gov/pubmed/29312305 http://dx.doi.org/10.3389/fimmu.2017.01772 |
_version_ | 1783286802957729792 |
---|---|
author | Borriello, Francesco Pietrasanta, Carlo Lai, Jacqueline C. Y. Walsh, Lois M. Sharma, Pankaj O’Driscoll, David N. Ramirez, Juan Brightman, Spencer Pugni, Lorenza Mosca, Fabio Burkhart, David J. Dowling, David J. Levy, Ofer |
author_facet | Borriello, Francesco Pietrasanta, Carlo Lai, Jacqueline C. Y. Walsh, Lois M. Sharma, Pankaj O’Driscoll, David N. Ramirez, Juan Brightman, Spencer Pugni, Lorenza Mosca, Fabio Burkhart, David J. Dowling, David J. Levy, Ofer |
author_sort | Borriello, Francesco |
collection | PubMed |
description | Immunization is key to preventing infectious diseases, a leading cause of death early in life. However, due to age-specific immunity, vaccines often demonstrate reduced efficacy in newborns and young infants as compared to adults. Here, we combined in vitro and in vivo approaches to identify adjuvant candidates for early life immunization. We employed newborn and adult bone marrow-derived dendritic cells (BMDCs) to perform a screening of pattern recognition receptor agonists and found that the stimulator of interferon genes ligand 2′3′-cGAMP (hereafter cGAMP) induces a comparable expression of surface maturation markers in newborn and adult BMDCs. Then, we utilized the trivalent recombinant hemagglutinin (rHA) influenza vaccine, Flublok, as a model antigen to investigate the role of cGAMP in adult and early life immunization. cGAMP adjuvantation alone could increase rHA-specific antibody titers in adult but not newborn mice. Remarkably, as compared to alum or cGAMP alone, immunization with cGAMP formulated with alum (Alhydrogel) enhanced newborn rHA-specific IgG2a/c titers ~400-fold, an antibody subclass associated with the development of IFNγ-driven type 1 immunity in vivo and endowed with higher effector functions, by 42 days of life. Highlighting the amenability for successful vaccine formulation and delivery, we next confirmed that cGAMP adsorbs onto alum in vitro. Accordingly, immunization early in life with (cGAMP+alum) promoted IFNγ production by CD4(+) T cells and increased the proportions and absolute numbers of CD4(+) CXCR5(+) PD-1(+) T follicular helper and germinal center (GC) GL-7(+) CD138(+) B cells, suggesting an enhancement of the GC reaction. Adjuvantation effects were apparently specific for IgG2a/c isotype switching without effect on antibody affinity maturation, as there was no effect on rHA-specific IgG avidity. Overall, our studies suggest that cGAMP when formulated with alum may represent an effective adjuvantation system to foster humoral and cellular aspects of type 1 immunity for early life immunization. |
format | Online Article Text |
id | pubmed-5732947 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-57329472018-01-08 Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization Borriello, Francesco Pietrasanta, Carlo Lai, Jacqueline C. Y. Walsh, Lois M. Sharma, Pankaj O’Driscoll, David N. Ramirez, Juan Brightman, Spencer Pugni, Lorenza Mosca, Fabio Burkhart, David J. Dowling, David J. Levy, Ofer Front Immunol Immunology Immunization is key to preventing infectious diseases, a leading cause of death early in life. However, due to age-specific immunity, vaccines often demonstrate reduced efficacy in newborns and young infants as compared to adults. Here, we combined in vitro and in vivo approaches to identify adjuvant candidates for early life immunization. We employed newborn and adult bone marrow-derived dendritic cells (BMDCs) to perform a screening of pattern recognition receptor agonists and found that the stimulator of interferon genes ligand 2′3′-cGAMP (hereafter cGAMP) induces a comparable expression of surface maturation markers in newborn and adult BMDCs. Then, we utilized the trivalent recombinant hemagglutinin (rHA) influenza vaccine, Flublok, as a model antigen to investigate the role of cGAMP in adult and early life immunization. cGAMP adjuvantation alone could increase rHA-specific antibody titers in adult but not newborn mice. Remarkably, as compared to alum or cGAMP alone, immunization with cGAMP formulated with alum (Alhydrogel) enhanced newborn rHA-specific IgG2a/c titers ~400-fold, an antibody subclass associated with the development of IFNγ-driven type 1 immunity in vivo and endowed with higher effector functions, by 42 days of life. Highlighting the amenability for successful vaccine formulation and delivery, we next confirmed that cGAMP adsorbs onto alum in vitro. Accordingly, immunization early in life with (cGAMP+alum) promoted IFNγ production by CD4(+) T cells and increased the proportions and absolute numbers of CD4(+) CXCR5(+) PD-1(+) T follicular helper and germinal center (GC) GL-7(+) CD138(+) B cells, suggesting an enhancement of the GC reaction. Adjuvantation effects were apparently specific for IgG2a/c isotype switching without effect on antibody affinity maturation, as there was no effect on rHA-specific IgG avidity. Overall, our studies suggest that cGAMP when formulated with alum may represent an effective adjuvantation system to foster humoral and cellular aspects of type 1 immunity for early life immunization. Frontiers Media S.A. 2017-12-12 /pmc/articles/PMC5732947/ /pubmed/29312305 http://dx.doi.org/10.3389/fimmu.2017.01772 Text en Copyright © 2017 Borriello, Pietrasanta, Lai, Walsh, Sharma, O’Driscoll, Ramirez, Brightman, Pugni, Mosca, Burkhart, Dowling and Levy. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Borriello, Francesco Pietrasanta, Carlo Lai, Jacqueline C. Y. Walsh, Lois M. Sharma, Pankaj O’Driscoll, David N. Ramirez, Juan Brightman, Spencer Pugni, Lorenza Mosca, Fabio Burkhart, David J. Dowling, David J. Levy, Ofer Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization |
title | Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization |
title_full | Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization |
title_fullStr | Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization |
title_full_unstemmed | Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization |
title_short | Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization |
title_sort | identification and characterization of stimulator of interferon genes as a robust adjuvant target for early life immunization |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732947/ https://www.ncbi.nlm.nih.gov/pubmed/29312305 http://dx.doi.org/10.3389/fimmu.2017.01772 |
work_keys_str_mv | AT borriellofrancesco identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization AT pietrasantacarlo identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization AT laijacquelinecy identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization AT walshloism identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization AT sharmapankaj identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization AT odriscolldavidn identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization AT ramirezjuan identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization AT brightmanspencer identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization AT pugnilorenza identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization AT moscafabio identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization AT burkhartdavidj identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization AT dowlingdavidj identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization AT levyofer identificationandcharacterizationofstimulatorofinterferongenesasarobustadjuvanttargetforearlylifeimmunization |